Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Shares Issued: 2015-2024

Historic Shares Issued for Aclaris Therapeutics (ACRS) over the last 10 years, with Dec 2024 value amounting to $74.9 million.

  • Aclaris Therapeutics' Shares Issued was N/A to $74.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was $45.7 million, marking a year-over-year change of. This contributed to the annual value of $74.9 million for FY2024, which is 180.43% up from last year.
  • According to the latest figures from FY2024, Aclaris Therapeutics' Shares Issued is $74.9 million, which was up 180.43% from $26.7 million recorded in FY2023.
  • In the past 5 years, Aclaris Therapeutics' Shares Issued registered a high of $74.9 million during FY2024, and its lowest value of $70,000 during FY2020.
  • In the last 3 years, Aclaris Therapeutics' Shares Issued had a median value of $72.7 million in 2022 and averaged $58.1 million.
  • Its Shares Issued has fluctuated over the past 5 years, first plummeted by 66.18% in 2020, then soared by 4,885.88% in 2022.
  • Aclaris Therapeutics' Shares Issued (Yearly) stood at $70,000 in 2020, then soared by 1,984.29% to $1.5 million in 2021, then soared by 4,885.88% to $72.7 million in 2022, then tumbled by 63.28% to $26.7 million in 2023, then surged by 180.43% to $74.9 million in 2024.